Analysis from FVSG identified 36pts with anti-rituximab antibodies In AAV, lookout for this in pts who are MPO+ & w/higher CD19 at 6 mos. Worse relapse free survival in both AAV & CRYO! @TerrierBen can you share the prevalence of these abs? #ACR25 @RheumNow #ACRBest abstr#1604 https://t.co/Nyx6JxbvUk

• https://x.com/EBRheum/status/1982837442140148004/photo/1
• https://x.com/EBRheum/status/1982837442140148004/photo/1

A combined biomarker assay may predict which AAV patients will not respond to RTX therapy A next step towards precision / personalized rheumatology? @RheumNow #ACR25 Abst 1602 https://t.co/gcrZUNV0b9

• https://x.com/Dr_Brian_MD/status/1982836045298184565/photo/1
• https://x.com/Dr_Brian_MD/status/1982836045298184565/photo/1

Safety & benefit of #Deucravacitinib in #SLE #LTE #PAISLEY #RCT 👇 over 4 yrs Stable response sustained over 4 yrs No new Safety signals Await Ph3 RCT results - fully enrolled #SoTyktu Abst#LB10 #ACR25 @RheumNow @ACRheum https://t.co/ZpmzOYVnq9

• https://x.com/Janetbirdope/status/1982835982748745866/photo/1

#1639 In 2 lupus cohorts (n=619), 1 in 4 had mismatch between self-reported & measured physical function. Higher BMI, disease activity & depression linked to underreporting ability ➡️ self-report ≠ performance! Important for SLE care & research. @RheumNow #ACR25 https://t.co/kMlChreJPh

• https://x.com/DrMiniDey/status/1982835932630781996/photo/1

Avouac et al. Lipid changes after JAKi initiation. 85 patients. Increases at 6 months. Largely appeared driven by HDL increase, and correlated CRP decrease. Appeared transient with return to baseline with time. @RheumNow #ACR25 Abstr#1333 https://t.co/CQ6u3ck1Ch

• https://x.com/RichardPAConway/status/1982835680926458297/photo/1

Ultra-low dose (ULD) RTX in AAV maintenance 200mg q6 mo vs. 500mg q6 mo interim analysis No major difference in infection risk or hypogammaglobulinemia thus far but both doses appeared similarly efficacious #ACR25 @rheumnow Abst 1609 https://t.co/ZGYNVGY3dr

• https://x.com/Dr_Brian_MD/status/1982835119527493687/photo/1

ADA-biosimilar use surged just before CVS formulary change then dropped sharply after. In RISE data, uptake reached 25% of users overall. Formulary policies reshape prescribing, but sustaining adoption needs alignment with patient access and preferences. @RheumNow #ACR25 A#1042

In this MTX+PNL vs TCZ+PNL in GCA study, we saw 5 pts on MTX+PNL get PJP, very surprising. @EBRheum asked what I knew/hoped he’d ask: why did this happen? PJP is v rare in GCA (https://t.co/oPN0dpvG8Q) & with MTX in other diseases. Worth interrogation! #ACR25 ABST0891 @RheumNow https://t.co/rsbScryIFR

• https://www.sciencedirect.com/science/article/abs/pii/S0049017222002050
• https://x.com/drdavidliew/status/1982831653023256722/photo/1

GLP-1 receptor agonists reduce mortality in PsA Tsibadze et al retrospectively compared ~4k PsA on GLP-1 to ~86k PsA not After propensity matching, those treated with GLP-1: - lower risk MACE - lower risk overall death @RheumNow #ACR25 Abst 0849 https://t.co/EuojrDq0Fj

• https://x.com/Dr_Brian_MD/status/1982830407365341680/photo/1

Is MTX worth anything in GCA? METOGiA: MTX 52w vs TCZ 52w for GCA MTX didn’t achieve non-inferiority to TCZ, but: - clearly it does something - continue both >1y: after MTX/TCZ therapy ended, they ended up with same relapse-free survival, cumulative GC #ACR25 ABST0891 @RheumNow https://t.co/WvvkHKIXuQ

• https://x.com/drdavidliew/status/1982829882553082184/photo/1
• https://x.com/drdavidliew/status/1982829882553082184/photo/1
• https://x.com/drdavidliew/status/1982829882553082184/photo/1

Open-label MTX vs. Toci in GCA in METOGiA Wk 78: 37% w/o relapse in MTX arm 46% w/o relapse in Toci arm MTX was NOT non-inferior to Toci Toci superior in 2ndary endpoints Cumulative doses GC not significantly different #ACR25 #ACRBest @RheumNow Abst 0891 https://t.co/lCaP4EdJ9C

• https://x.com/Dr_Brian_MD/status/1982827205349789731/photo/1

REPLENISH - Secukinumab Works in Polymyalgia Rheumatica Novartis announced the results of their REPLENISH trial showing the efficacy of secukinumab (Cosentyx) (SEC) in adults with polymyalgia rheumatica (PMR). https://t.co/CLmCdBXiOf https://t.co/z20nWd2NSM

• REPLENISH - Secukinumab Works in Polymyalgia Rheumatica | RheumNow

Next Generation T-Cell Engager: The Future https://t.co/gcrfzV6MSJ via @YouTube @alhkim great to see you and hearing all about new T cell Engager , feasibility and less toxicity. @RheumNow #ACR25

• Next Generation T-Cell Engager: The Future

#0851 Urinary Tenascin C predicts kidney function loss in lupus nephritis 170 AMP-LN patients: Tenascin C (from renal myofibroblasts) was the top predictor of eGFR decline (HR 4.6) Proteomic 11-marker risk score (AUC 0.91) outperformed proteinuria for prognosis #ACR25 @RheumNow

#0852 LEVI-04, a novel p75NTR-Fc fusion protein, significantly reduces MRI bone marrow lesions in knee #OA 🦵📉 Phase II RCT (n=518): dose-dependent BML reduction (p<0.001) + correlated improvement in pain & function. Promising structure-modifying OA therapy @RheumNow #ACR25 https://t.co/huA8OaFGSd

• https://x.com/DrMiniDey/status/1982810011932975609/photo/1